| Authors: |
Kamal NS; Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality (OPQ), CDER, FDA, USA. Electronic address: nahid.kamal@fda.hhs.gov., Acheampong S; Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality (OPQ), CDER, FDA, USA., Zaman RU; Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality (OPQ), CDER, FDA, USA., Strasinger C; Office of Pharmaceutical Quality Assessment II, OPQ, CDER, FDA, USA., Clark AG; digiM Solution 500 West Cummings Park, Woburn, MA 01801, USA., Zhu A; digiM Solution 500 West Cummings Park, Woburn, MA 01801, USA., Tang Y; Office of Pharmaceutical Quality Assessment III, OPQ, CDER, FDA, USA., Zidan A; Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality (OPQ), CDER, FDA, USA., Ashraf M; Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality (OPQ), CDER, FDA, USA. |
